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Aim. Identification of candidate secreted biomarkers for hepatocellular carcinoma (HCC) diagnosis. Methods. 
Genes upregulated in HCC tissue and encoding secreted proteins were identified by RNA-seq. Gene expres-
sion changes in HCC were evaluated by RT-qPCR and meta-analysis of public databases. Biomarker proper-
ties were studied using ROC-curves, correlation and survival analysis. Results. PDGFA was identified by 
RNA-seq as an overexpressed gene encoding for a secreted protein in 5 HCC cases. PDGFA and GPC3 up-
regulation was revealed in 17 of 19 HCC samples and in most cases from the public databases. Combination 
of PDGFA and GPC3 discerned HCC and non-tumor tissue better than PDGFA or GPC3 alone. PDGFA 
overexpression was associated with better overall survival of the patients at early HCC stage and with weaker 
tumor invasion into blood vessels. Conclusion. PDGFA is a valuable secreted biomarker for HCC that might 
be used in combination with GPC3 to increase its sensitivity.
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Introduction
Hepatocellular carcinoma (HCC) is the most com-
mon form of malignant liver tumors with extremely 
high aggressiveness and poor prognosis. HCC ranks 
the second place in cancer-related mortality rates 
while most HCC patients are diagnosed at advanced 
stages when the existing therapeutic approaches be-
come inefficient [1,2].
The major difficulty in improving HCC diagnosis 
and treatment is imposed by a high heterogeneity of 
the genetic and signaling aberrations observed in 
HCC and poor understanding of molecular mecha-
nisms underlying its development. Thus, the identifi-
cation of new biomarkers suitable for an early diag-
nosis and potential therapeutic targets is an impor-
tant field in improving the efficiency of HCC ma na-
gement [3].
Alpha-fetoprotein (AFP), the only HCC marker 
approved for clinical practice, has low sensitivity for 
early tumor detection [4,5]. Among additional HCC 
biomarkers under investigation, glypican-3 (GPC3) 
is the most promising one that demonstrates high 
sensitivity and specificity in tumor tissue but per-
forms worse when detected in blood serum. The ef-
ficiency of HCC diagnosis can be improved by using 
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combinations of biomarkers but remains insufficient 
to confidently detect HCC at early stages [5,6].
The next-generation sequencing (NGS) approa-
ches open new possibilities in disclosing the mole-
cular basis of carcinogenesis. The genomic and tran-
scriptomic data revealed the multiple tumor-specific 
mutations and gene expression changes that can be 
further analyzed to identify putative biomarkers and 
changes in the signaling pathways regulating HCC 
progression. The present work is devoted to identifi-
cation of novel prospective HCC biomarkers based 
on the results of transcriptome sequencing and in-
vestigation of their potential impact using experi-
mental and bioinformatic approaches.
Materials and Methods
Samples collection, RNA extraction, transcriptome 
sequencing and differential expression analysis
19 pairs of tumor and adjacent non-tumorous (NT) 
liver tissues were collected after tumor resection 
from the patients with histologically verified HCC 
not associated with hepatitis virus infection. The 
samples were collected with informed consent, con-
forming to the ethical guidelines of the 1975 
Declaration of Helsinki, frozen in liquid nitrogen 
and stored at –80 °C. The clinicopathological data 
on collected cases are presented in Table 1. 
Total RNA was isolated as previously de-
scribed [7]. Illumina HiSeq2000 100 nt pair-end 
transcriptome sequencing was performed for 5 pairs 
of tumor and liver tissue in two biological replicates. 
Library preparation, transcriptome sequencing, read 
processing and differential expression analysis were 
performed as previously described [7].
Quantitative Real-Time PCR
Total RNA was reverse transcribed using random 
hexanucleotide primers and MMLV reverse tran-
scriptase (Promega, USA).
Real-time RT-qPCR was carried out using SYBR 
Green I PCR kit (Syntol, Russian Federation) and 
iQ5 Multicolor Real-Time PCR Detection System 
(Bio-Rad Laboratories, USA). TATA-binding pro-
tein gene (TBP) was used as a reference gene. 45 
cycles of amplification (30 s at 95 °C, 30 s at anneal-
ing temperature (PDGFA – 66.0 °C, GPC3 – 67.7 °C, 
TBP – 62.8 °C), 30s at 72 °C) were performed and 
the reaction specificity was checked afterwards by a 
melt curve analysis. The gene expression levels were 
estimated using a standard curve for fixed signal 
value. For each sample, the gene expression level 
was normalized to TBP expression, logarithm to 
base 2 was taken from normalized value and differ-
ence between the values obtained for HCC and cor-
responding NT samples was calculated.
The following primers were used for reactions: 
PDGFA-forward 5’-ACCACCGCAGCGTCAAGG- 
3’, PDGFA-reverse 5’-GCGGCTCATCCTCACCTC 
AC-3’, GPC3-forward 5’-GCAGGAAAGCTGACC 
ACCAC-3’, GPC3-reverse 5’-AGTTCCCTTCTTC 
GGCTGGAT-3’, TBP-forward 5’-TGCACAGGAGC 
CAAGAGTGA-3’, TBP-reverse 5’-ACTTCACATC 
ACAGCTCCCCA-3’.
Table 1. Clinicopathological data on HCC patients enrolled 
in present study.
Characteristics
Number 
of cases 
(n=19)
Age, years (mean±SD) 48.1±19.2
Gender, male/female 11/8
TNM staging, I/II/III/IV 4/4/6/5
Tumor size, cm (mean ± SD) 10.1±5.6
Tumor capsule, absent/feeble/prominent/N/A1 4/9/5/1
Blood vessel invasion, yes/no 11/8
Tumor vascularity, low/moderate/high/N/A 2/5/5/7
Histological differentiation,
Edmondson-Steiner grade, G1/G2/G3/Gx2
3/8/3/5 
Intrahepatic metastases, yes/no 8/11 
Lymph node metastases, yes/no 3/16
Distant metastases, yes/no 1/18
AFP serum level, 
low (<50 ng/ml)/high (>50 ng/ml) 9/9
Cirrhosis, yes/no 5/14
Tumor necrosis, yes/no 12/7
1 N/A – data not available  
2 Gx – Edmondson-Steiner grade not applicable
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Table 2. MIQE qPCR information table.
Item to check Importance Information
EXPERIMENTAL DESIGN
Definition of experimental and 
control groups E
Experimental group consisted of HCC tissue samples and control group 
consisted of corresponding samples of non-tumorous liver tissue taken from 
same patients
Number within each group E 19 samples within each group
Assay carried out by the core or 
investigator’s laboratory?
D Investigator’s laboratory
Acknowledgment of authors’ 
contributions D
SAMPLE
Description E Tissue samples of HCC and non-tumorous liver tissue taken from patients 
diagnosed with HCC after tumor resection
Volume/mass of sample 
processed D Approximately 20 mg of tissue
Microdissection or macrodissection E Macrodissection
Processing procedure E
Tissue samples were taken immediately after tumor resection with sterile 
scalpel and incubated in RNAlater Stabilization Solution (Thermo Fisher 
Scientific AM7024, USA) for 24 hours at 4 °C. Then RNAlater Stabilization 
Solution was removed and samples were frozen
If frozen, how and how quickly? E Samples were frozen at –70 °C immediately after RNAlater Stabilization Solution treatment
If fixed, with what and how 
quickly?
E Samples were not fixed
Sample storage conditions and 
duration E Frozen samples were stored at –70 °C
NUCLEIC ACID EXTRACTION
Procedure and/or 
instrumentation E
Frozen samples were homogenized using glass Potter grinder cooled with 
liquid nitrogen and transferred into RNase-free tubes
Name of kit and details of any 
modifications
E
RNA was extracted from homogenized samples using PureLink RNA Mini 
Kit (Thermo Fisher Scientific 12183018A, USA) with additional on-column 
DNase treatment according to manufacturer’s manual
Source of additional reagents used D Thermo Fisher Scientific, USA
Details of DNase or RNase 
treatment E
On-column DNase treatment was performed with PureLink DNase Set (Thermo 
Fisher Scientific 12185010, USA) according to manufacturer’s manual
Contamination assessment 
(DNA or RNA) E
Contamination of RNA samples by protein or organic chemical compounds 
was evaluated by measuring optical density at 260, 280 and 230 nm. 
Contamination of RNA samples by genomic DNA was evaluated by 
using control sample without reverse transcriptase added during reverse 
transcription step
Nucleic acid quantification E RNA concentration was evaluated by measuring optical density at 260 nm
Instrument and method E NanoDrop ND-1000 spectrophotometer (Thermo Scientific, USA)
Purity (A260/A280) D All examined RNA samples had A260/A280 ratio higher than 2.0
Yield D Approximately 20 μg of total RNA were extracted from one tissue sample 
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Item to check Importance Information
RNA integrity: method/
instrument E
RNA integrity was evaluated using Agilent 2100 Bioanalyzer (Agilent 
Technologies, USA)
RIN/RQI or Cq of 3’ and 5’ 
transcripts E Only samples with RIN (RNA integrity number) > 7 were taken for analysis
Electrophoresis traces D Electrophoresis was not used
Inhibition testing (Cq dilutions, 
spike, or other) E
Standard calibration curve was used for evaluating possible PCR inhibitor 
contamination; PCR efficiency of 98 %–102 % was considered applicable 
REVERSE TRANSCRIPTION
Complete reaction conditions E
Total RNA was reverse transcribed using random hexanucleotide primers and 
RevertAid Reverse Transcriptase. Mix of hexanucleotide primers and total 
RNA template (total volume 12.25 μl) was incubated at 70 °C for 10 min 
and cooled at 4 °C. After that, 7.75 μl of reaction mix containing RevertAid 
Reaction buffer for RT, dNTPs, DTT, Ribo-Lock RNase inhibitor and 
RevertAid Reverse Transcriptase was added. Final concentrations of reagents 
were 5 ng/μl hexanucleotide primers, 0.25 mM each dNTP, 100 μM DTT, 
1 U/μl Ribo-Lock and 2.5 U/μl RevertAid RT. Reaction mix was incubated at 
42 °C for 60 min, at 95 °C for 10 min and cooled at 4 °C.
Amount of RNA and reaction 
volume E
2 μg of total RNA was used for RT reaction. Reaction volume for incubation 
of RNA with hexanucleotide primers was 12.25 μl and reaction volume for RT 
reaction was 20 μl
Priming oligonucleotide (if 
using GSP) and concentration E Random hexanucleotide primers, 5 ng/μl
Reverse transcriptase and 
concentration E RevertAid Reverse Transcriptase, 2.5 U/μl
Temperature and time E See “Complete reaction conditions” subsection
Manufacturer of reagents and 
catalogue numbers D
Random hexanucleotide primers (Syntol, Russian Federation)
dNTPs (Syntol dNTP-100-010, Russian Federation)
DTT (Sigma-Aldrich D9779-10G, USA)
Ribo-Lock RNase inhibitor (Thermo Fisher Scientific EO0381, USA)
RevertAid Reverse Transcriptase (Thermo Fisher Scientific EP0441, USA)
RevertAid 5X Reaction buffer for RT (Thermo Fisher Scientific EP0441, USA)
Cqs with and without reverse 
transcription D
Cq for experimental samples was within the range of 20–35 cycles, no 
amplification or very low non-specific amplification was observed in samples 
without reverse transcription (Cq>40 cycles)
Storage conditions of cDNA D Resulting cDNA samples were diluted up to 100 μl by double-distilled water and stored at –20 °C
qPCR TARGET INFORMATION
Gene symbol E TBP; PDGFA; GPC3
Sequence accession number E
TBP - NM_003194.4
PDGFA - NM_002607.5
GPC3 - NM_001164617.1
Location of amplicon D Amplicons were located in conservative regions of target gene mRNAs to amplify all possible isoforms
Amplicon length E
TBP – 136 b.p.
PDGFA – 166 b.p. and 235 b.p. 
GPC3 – 161 b.p. and 230 b.p. (not detected) 
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Item to check Importance Information
In silico specificity screen 
(BLAST, and so on) E
All primers were checked for specificity using NCBI Primer-BLAST service 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/)
Pseudogenes, retropseudogenes, 
or other homologs?
D Primers were designed to prevent amplification of homologous templates
Sequence alignment D Not evaluated
Secondary structure analysis of 
amplicon D Not evaluated
Location of each primer by exon 
or intron (if applicable) E
TBP-forward – exon 5 of NM_003194.4 transcript
TBP-reverse – exon 6 of NM_003194.4 transcript
PDGFA-forward – exon 4 of NM_002607.5 transcript
PDGFA-reverse – exon 7 of NM_002607.5 transcript
GPC3-forward – exon 3 5 of NM_004484.3 transcript
GPG3-reverse – exon 5 of NM_004484.3 transcript
What splice variants are 
targeted?
E
TBP - NM_001172085, NM_003194
PDGFA - NM_002607, NM_033023
GPC3 - NM_001164617, NM_001164618, NM_001164619, NM_004484
qPCR OLIGONUCLEOTIDES
Primer sequences E
TBP-forward – 5’-TGCACAGGAGCCAAGAGTGA-3’
TBP-reverse – 5’-ACTTCACATCACAGCTCCCCA-3’
PDGFA-forward – 5’-ACCACCGCAGCGTCAAGG-3’
PDGFA-reverse – 5’-GCGGCTCATCCTCACCTCAC-3’
GPC3-forward – 5’-GCAGGAAAGCTGACCACCAC-3’
GPC3-reverse – 5’-AGTTCCCTTCTTCGGCTGGAT-3’
RTPrimerDB identification 
number D Not applicable
Probe sequences D Not applicable
Location and identity of any 
modifications
E Not applicable
Manufacturer of oligonucleotides D Syntol, Russian Federation
Purification method D PAAG electrophoresis
qPCR PROTOCOL
Complete reaction conditions E
PCR was performed using SYBR Green I PCR kit (Syntol R-402, Russian 
Federation). Reaction mix contained cDNA template, PCR buffer with SYBR 
Green I dye, dNTPs, MgCl2, oligonucleotide primers and SynTaq DNA 
polymerase. Following PCR protocol was used:
Initial denaturation – 5 min at 95 °C
45 PCR cycles – 30 sec at 95 °C, 30 sec at primer annealing temperature 
(PDGFA – 66.0 °C, GPC3 – 67.7 °C, TBP – 62.8 °C), 30 sec at 72 °C
Final elongation – 3 min at 72 °C
Melt curve analysis – from 60 °C up to 100 °C with increment of 0.5 °C
Reaction volume and amount of 
cDNA/DNA E
PCR was performed in a volume of 25 μl, cDNA sample (see “Storage 
conditions of cDNA” subsection) was diluted ten-times and 10 μl of diluted 
cDNA sample were added to the reaction mix
Primer, (probe), Mg2+, and 
dNTP concentrations E 0.4 μM of each primer, 2.5 μM Mg
2+, 0.25 mM dNTPs
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Item to check Importance Information
Polymerase identity and 
concentration E SynTaq DNA polymerase (Syntol E-039-1000, Russian Federation)
Buffer/kit identity and 
manufacturer E SYBR Green I PCR kit (Syntol R-402, Russian Federation).
Exact chemical composition of 
the buffer D Not specified by manufacturer
Additives (SYBR Green I, 
DMSO, and so forth) E SYBR Green I dye was pre-added to PCR buffer by manufacturer
Manufacturer of plates/tubes and 
catalog number D 0.2 ml PCR strips with domed caps (SSI 3240-00, USA)
Complete thermocycling 
parameters E See “Complete reaction conditions” subsection
Reaction setup (manual/robotic) D Manual
Manufacturer of qPCR 
instrument E
iCycler Thermal Cycler with iQ5 Multicolor Real-Time PCR Detection 
System, data were analyzed using iQ5 Optical System Software (Bio-Rad 
Laboratories, USA)
qPCR VALIDATION
Evidence of optimization (from 
gradients) D
Primer annealing temperature was optimized for each primer set using qPCR 
with temperature gradient to achieve reaction efficiency of 98 %-102 % and 
minimize non-specific amplification
Specificity (gel, sequence, melt, 
or digest) E Specificity of qPCR was determined using melt curve analysis
For SYBR Green I, Cq of the 
NTC E
No amplification or very low non-specific amplification was observed in 
samples without reverse transcription and in NTC samples (Cq>40 cycles)
Calibration curves with slope 
and y intercept E
Slope and y intercept values:
TBP – slope=-3.283, y int=31.467
PDGFA – slope=-3.339, y int=30.015
GPC3 – slope=-3.301, y int=26.564
PCR efficiency calculated from 
slope E
TBP – E=101.6 %
PDGFA – E=99.3 %
GPC3 – E=100.9 %
CIs for PCR efficiency or SE D Not evaluated
r2 of calibration curve E
TBP – E=0.996
PDGFA – E=0.998
GPC3 – E=0.998
Linear dynamic range E Standard curve was linear within the limits of cDNA dilutions from non-diluted samples up to 1/10000 dilution for all primers used
Cq variation at LOD E
SD of Cq values for 1/10000 dilution sample:
TBP – 0.83
PDGFA – 0.77
GPC3 – 0.37
CIs throughout range D Not evaluated
Evidence for LOD E High variation of Cq values obtained for 1/10000 dilution sample 
If multiplex, efficiency and LOD 
of each assay E Displayed above
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Item to check Importance Information
DATA ANALYSIS
qPCR analysis program (source, 
version) E
Data were analyzed using iQ5 Optical System Software, v2.0 (Bio-Rad 
Laboratories, USA)
Method of Cq determination E
Cq values were determined by setting a signal threshold. Threshold value was 
adjusted to detect the amplification of samples during log-phase of PCR and at 
the same time to be significantly higher than background signal
Outlier identification and 
disposition E
Data were checked for outliers using Grubbs’ test, no significant outliers were 
detected
Results for NTCs E No amplification or very low non-specific amplification was observed in samples without reverse transcription and in NTC samples (Cq>40 cycles)
Justification of number and 
choice of reference genes E
TBP was chosen as a reference gene based on lowest variability of its 
expression level in 10 samples (5 HCC samples and 5 corresponding 
non-tumorous tissue samples) examined by RNAseq approach. Low TBP 
expression variability was validated on TCGA-LIHC RNAseq dataset 
(see Materials and Methods). This experimental evidence is supported by 
previously published data [9, 10] while the expression of other reference gene, 
HPRT was found to be variable in some non-HBV related HCC samples.
Description of normalization 
method E
For each sample, target gene expression was normalized to TBP expression. 
Level of target gene expression was divided by level of TBP expression prior 
to comparing different samples
Number and concordance of 
biological replicates D
Not applicable since one HCC tissue and one non-tumorous tissue samples 
were taken from each patient
Number and stage (reverse 
transcription or qPCR) of 
technical replicates
E At least 3 technical replicates were analyzed in each qPCR reaction
Repeatability (intraassay variation) E Average CV for technical replicates was 0.22
Reproducibility (interassay 
variation, CV) D Not evaluated
Power analysis D Not evaluated
Statistical methods for results 
significance
E
Changes in expression level that were higher than 2-fold were considered 
significant when comparing HCC and non-tumorous tissue samples from same 
patient. Differences between gene expression levels in HCC and NT sample 
sets were estimated using paired sample sign test (for sets of paired samples) 
and Mann-Whitney U-test (for sets of unpaired samples).
Software (source, version) E Origin Pro 2016 software (OriginLab Corporation, USA)
Cq or raw data submission with 
RDML D Not submitted
All relevant qPCR conditions and characteristics 
determined by the MIQE Guidelines [8] are de-
scribed in Table 2.
Hepatocellular carcinoma datasets
Publicly available datasets containing information 
on gene expression in paired liver-HCC samples and 
their clinical data were acquired from GEO database 
(https://www.ncbi.nlm.nih.gov/geo): GSE14520 
[11], GSE25599 [12], GSE5364 [13], GSE65485 
[14], GSE77314 [15]. PDGFA expression data gen-
erated using 205463_s_at probe set were considered 
for GSE14520 as it targets both PDGFA isoforms.
TCGA Liver Hepatocellular Carcinoma (TCGA-
LIHC) set that comprised information on the normal-
ized gene expression in 51 matched liver and tumor 
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Table 3. Potential secreted HCC markers that were significantly upregulated in 5 sequenced HCC cases
Symbol (Entrez Gene ID) Average fold change of 
gene expression Si
gn
al
P
T
M
H
M
M
G
en
e 
C
ar
ds
Pr
ot
ei
n 
A
tla
s
Li
te
ra
tu
re Average FPKM
Liver tissue Tumor
VCAN (1462) 113.67(14.61–261.68) + – + + +
0.25
(0.20–0.30)
36.07
(7.39–74.95)
CCDC80 (151887) 27.02(7.30–54.85) + – + + +
0.32
(0.15–0.41)
9.63
(3.88–12.10)
COL1A1 (1277) 33.41(19.85–49.81) + – + + +
0.63
(0.37–0.93)
37.27
(13.55–52.08)
SMOC2 (64094) 20.32(7.67–34.26) + – + + +
0.15
(0.05–0.43)
3.07
(2.00–4.50)
LTBP2 (4053) 28.97(11.58–56.28) + – + + +
0.19
(0.10–0.29)
6.53
(2.89–10.52)
COL5A1 (1289) 9.92(6.30–14.57) + – + + +
0.50
(0.40–0.69)
8.16
(3.85–16.13)
PDGFA (5154) 18.99(8.04–38.57) + – + + +
0.14
(0.09–0.24)
4.19
(2.16–7.75)
ITGBL1 (9358) 16.38(5.61–23.86) + – + + +
0.30
(0.14–0.68)
5.48
(2.97–7.65)
COL15A1 (1306) 134.11(30.05–314.65) + – + + +
0.06
(0.04–0.09)
6.76
(3.00–14.23)
tissues and 321 tumors corresponding to a pooled nor-
mal sample was obtained from The Cancer Genome 
Atlas Network (https://gdc-portal.nci.nih.gov/) through 
FireBrowse (http://www.firebrowse.org). The clinical 
and survival data were downloaded at cBioPortal 
(http://www.cbioportal.org).
Statistical analysis
Each tissue sample used for RT-qPCR was analyzed 
in at least four technical replicates and a mean value 
was used for further analysis. The statistical analysis 
of results and plotting of graphs were performed using 
Origin Pro 2016 software (OriginLab Corporation, 
USA). The differences between gene expression lev-
els in HCC and NT samples were estimated using a 
paired sample sign test (for paired samples) and 
Mann-Whitney U-test (for unpaired samples). The 
empirical distribution curves for gene expression in 
different datasets were compared using Kolmogorov-
Smirnov test. The hierarchical cluster analysis of gene 
expression datasets was performed using Euclidean 
distance and Complete linkage algorithm. Receiver 
operating characteristic (ROC) curve discriminative 
power analysis was performed using the normalized 
gene expression level for classifier, HCC samples for 
estimation of true positive rate and NT samples from 
the same patients for estimation of false positive rate. 
The combined PDGFA+GPC3 classifier for ROC 
curves was generated by applying a logistic regres-
sion model to the data on both PDGFA and GPC3 ex-
pression levels and taking the values of expected 
probabilities as a new classifier. The correlations were 
evaluated using Spearman’s rank correlation test. A 
survival analysis was performed using Kaplan-Meyer 
test with log-rank significance estimation algorithm. 
Statistical significance was accepted with p<0.05.
Results
The whole transcriptome data analysis using DESeq 
[16] revealed 83 differentially expressed (DE) 
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Fig. 1. Alteration of PDGFA (A, B) and GPC3 (C, D) expression in examined HCC tissue samples. A, C — RT-qPCR analysis of 
PDGFA or GPC3 expression changes in HCC specimens relative to matching non-tumor liver tissue for individual cases. B, D — Box 
plot representation of TBP-normalized expression levels of PDGFA and GPC3 in examined sets of HCC and NT samples (n=19).
A
C
B
D
genes that were up-regulated more than 5-fold in 
all HCC samples as compared to corresponding ad-
jacent liver tissue. In order to identify putative se-
creted HCC markers, the FASTA sequences of all 
mRNA isoforms of DE genes were analyzed with 
SignalP Server 4.1 (http://www.cbs.dtu.dk/servic-
es/SignalP/) and TMHMM Server v. 2.0 (http://
www.cbs.dtu.dk/services/TMHMM/) using default 
settings. The genes harboring sequences that were 
predicted to encode the signal peptide cleavage 
sites but not transmembrane helices were examined 
using GeneCards (http://www.genecards.org/), The 
Human Protein Atlas (http://www.proteinatlas.org/) 
and the information from journal articles. Then we 
excluded the genes that were valuably expressed in 
normal liver (FPKM>1) and/or demonstrated rela-
tively low level of expression in tumors (FPKM<2). 
Thus, we obtained a list comprising 9 potential se-
creted HCC markers (Table 3).
The list of candidate serum markers includes 
growth factor PDGFA, a component of PDGF signal-
ing pathway identified in our recently published HCC 
427
Transcriptome-based identification of PDGFA as a candidate secreted biomarker for hepatocellular carcinoma
case report as a potential druggable target [7]. Since 
the proangiogenic and mitogenic stimulation promot-
ed by PDGF signaling can be blocked by a multiki-
nase inhibitor sorafenib, the only FDA approved drug 
for HCC treatment [17, 18], we have focused on in-
vestigation of the expression alterations of PDGFA 
that might be not only a candidate HCC marker but 
also a prospective target for drug treatment.
To explore HCC-specific changes in PDGFA ex-
pression we performed RT-qPCR analysis of PDGFA 
expression levels in 19 pairs of tumor and NT tissues 
from hepatitis-negative HCC patients. While low 
PDGFA expression levels were detected in all NT spec-
imens, the PDGFA expression in HCC tissue was up-
regulated more than two-fold in 17 of 19 (89.5 %) ex-
amined cases (Fig. 1A) and the difference between 
these two subsets was statistically significant (Fig. 1B). 
We investigated the potential of PDGFA usage as 
a biomarker by comparing its expression changes in 
HCC tissue to the expression changes of GPC3, the 
latter being a promising candidate biomarker for 
HCC [19]. RT-qPCR analysis revealed the signifi-
cant GPC3 overexpression in HCC compared to NT 
tissue (Fig. 1D) in 18 of 19 (94.7 %) cases (Fig. 1C). 
Spearman’s correlation analysis demonstrated that 
the changes in PDGFA expression were not associ-
ated with the clinicopathological properties of exam-
ined tumors.
In order to determine whether the PDGFA up-regula-
tion discovered in the examined sample set is a frequent 
event in HCC we performed meta-analysis of the gene 
expression data for paired HCC/NT samples obtained 
from six publicly available datasets (Table 4). Each of 
the analyzed datasets displayed a significant (more than 
2-fold) up-regulation of the PDGFA transcription in tu-
mor tissue compared to the corresponding surrounding 
liver samples in no less than 50 % of cases. Since sev-
eral datasets comprised the data on a low number of 
samples, we further analyzed TCGA (“TCGA set”) and 
GSE14520 (“Roessler set”) datasets.
The ratios of cases with significant PDGFA up-
regulation ranged from 52.4 % (“Roessler set”) to 
63.8 % (“TCGA set”) (Fig. 2A). Median values of 
normalized PDGFA expression level were signifi-
cantly higher in cohorts of HCC tissue samples than 
in cohorts of corresponding NT specimens (Fig. 2B).
While both datasets support the observation of 
PDGFA up-regulation being a frequent event in HCC 
tissue, the percentage of PDGFA overexpressing 
samples is less than observed in our experimental 
set. To explore whether this difference could be as-
sociated with hepatitis infection we subtracted a 
fraction of 94 TCGA cases that were not marked as 
hepatitis-positive (hereinafter called “TCGA-HN 
set” for “hepatitis-negative”). The proportion of cas-
es with up-regulated PDGFA expression in “TCGA-
HN set” (68.1 %) (Fig. 2A) was very similar to the 
one observed in full “TCGA set”, while no statisti-
cally significant differences between full and “HN” 
sets in the context of PDGFA expression level me-
dian values (p=0.558 estimated by Mann-Whitney 
U-test) and the empirical distribution curve (p=0.988 
estimated by Kolmogorov-Smirnov test) were found 
thus indicating that PDGFA up-regulation in HCC 
occurs irrespectively of tumor etiology.
To evaluate the PDGFA potential sensitivity as a 
HCC biomarker we compared the PDGFA expression 
changes in “Roessler set” and “TCGA-HN set” to the 
alterations of GPC3 expression (Fig. 3A). While the 
Table 4. Overexpression of PDGFA in HCC in six datasets 
comprising paired normal-tumor samples.
Dataset ID 
N
um
be
r o
f c
as
es
H
B
V
-p
os
it
iv
e 
ca
se
s,
 %
PD
G
FA
 
ov
er
ex
pr
es
si
on
 in
 
tu
m
or
, %
 o
f 
ca
se
s
Gene expression 
profiling method
TCGA-LIHC 373 75 63.8 RNAseq
GSE14520 231 98 52.4
Affymetrix 
Human Genome 
HT U133A Array
GSE25599 10 100 50 RNAseq
GSE5364 8 N/A 100
Affymetrix 
HG U133A 
microarray
GSE77314 50 N/A 60 RNAseq
GSE65485 8 100 75 RNAseq
1 N/A – data not available
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Fig. 2. Alteration of PDGFA expression observed in publicly available HCC datasets. A — Distribution curves of PDGFA expression 
level changes in individual HCC samples compared to NT samples. B — Box plot representation of normalized expression levels of 
PDGFA in examined sets of HCC and NT samples.
A B
sensitivity of PDGFA (52.4 % for “Roessler set”, 68.1 % 
for “TCGA-HN set”) was lower than that of GPC3 
(87.4 % for “Roessler set”, 81.9 % for “TCGA-HN 
set”), the combination of PDGFA and GPC3 increased 
the sensitivity to 93.9 % for “Roessler set” and 93.6 % 
for “TCGA-HN set” (p=0.024 for both sets compared to 
GPC3 alone, estimated by Fisher’s exact test).
In order to evaluate the possibility of using the 
expression level of PDGFA, GPC3 or both genes as 
a parameter discerning HCC from NT tissue, we 
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generated ROC curves using the data for paired sam-
ples from “Roessler set” (n=231) and “TCGA-HN 
set” (n=24). Usage of the PDGFA+GPC3 combina-
tion increased the value of area under a curve (AUC) 
in comparison to PDGFA or GPC3 alone, thus indi-
cating a stronger discriminative power of the PDGFA 
and GPC3 combination (Fig. 3B).
A correlation analysis of the PDGFA expression 
changes and clinicopathological characteristics 
available for “TCGA-HN set” revealed a reverse 
correlation of the PDGFA up-regulation with the ex-
tent of tumor invasion into blood vessels. 
Since “Roessler set” contains the data on 
Barcelona Clinic Liver Cancer (BCLC) staging 
which is widely used for evaluation of prognosis and 
treatment algorithm for HCC patients [20] we ana-
lyzed an association between the PDGFA up-regula-
tion and overall and progression-free survival of pa-
tients belonging to different BCLC groups. The 
PDGFA overexpression in tumor tissue was associ-
ated with better overall survival of patients with 
early BCLC-0 and BCLC-A HCC stages but not in-
termediate BCLC-B or late BCLC-C stage (Fig. 4). 
No associations between the PDGFA overexpression 
A B
Fig. 3. Comparison of PDGFA and GPC3 expression changes in HCC and NT tissue samples from publicly available datasets. A — 
Heatmap representation of PDGFA and GPC3 expression changes in HCC specimens from “Roessler set” and “TCGA-HN set”. 
Color bar indicates the alteration of gene expression in tumor tissue relative to NT sample in log2 scale. B — ROC curves represent-
ing the ability of PDGFA, GPC3 or PDGFA+GPC3 combination to discriminate HCC and NT tissue samples.
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and progression-free survival were found (data not 
shown).
Discussion
The discovery of tumor biomarkers significantly im-
proved the outcome for cancer patients and opened 
new possibilities for early diagnosis and targeted 
treatment of malignant tumors [21]. The only serum 
HCC biomarker approved for clinical practice is 
AFP [4] that displays 59% sensitivity and 90% spec-
ificity [22]. Since AFP exhibits insufficient sensitiv-
ity for the confident HCC diagnosis, the additional 
markers to complement AFP and improve HCC di-
agnostic accuracy are under investigation [23].
Currently GPC3 is considered to be one of the 
most promising HCC candidate biomarkers. It can 
be detected at the mRNA level in liver tissue or at the 
protein level in serum or liver tissue. Immuno histo-
che mical detection of GPC3 demonstrates a high 
sensitivity for poorly-differentiated HCC but a lower 
sensitivity for highly-differentiated and fibrolamel-
lar variants [19]. The GPC3 mRNA was found to be 
overexpressed in more than 80 % of HCC cases as-
sociated with viral hepatitis and in 76 % of non-viral 
HCC cases [24]. However, the measuring of serum 
GPC3 level was less sensitive (55.2 %) while reta-
ining a high specificity (84.2 %). The GPC3 combi-
nation with AFP was uncovered to be more effective 
for HCC diagnosis with 75.7 % sensitivity and 
83.3 % specificity [25]. Thus, we have chosen GPC3 
as a “reference” HCC biomarker and compared the 
data obtained for PDGFA to the GPC3 performance.
Performed analysis of the expression data from 
our HCC set and publicly available databases re-
vealed the frequent PDGFA overexpression in HCC 
tissue. Though PDGFA was previously reported to 
be overexpressed in HCC [26], no detailed investi-
gation on its expression alteration or its potential as 
a HCC biomarker has been published to date. 
A high rate of PDGFA up-regulation in 19 exam-
ined hepatitis-negative HCC cases was comparable 
to that of GPC3. However, PDGFA did not perform 
so well in larger and less homogenous datasets exhib-
iting a lower sensitivity than GPC3. While most cas-
es from publicly available datasets demonstrated up-
regulation of both PDGFA and GPC3, there were 
subsets with mutually exclusive overexpression of 
PDGFA or GPC3 indicating that their combination 
could perform better than each biomarker separately. 
Indeed, if 2-fold increase in the expression level of 
either PDGFA or GPC3 was taken as cut-off, the sen-
sitivity of HCC detection considerably increased up 
to 93.6%. The analysis of biomarkers discriminatory 
power revealed that PDGFA and GPC3, when com-
bined, distinguished HCC from NT tissue of the same 
patients better than PDGFA or GPC3 individually. 
Fig. 4. Kaplan-Meyer analysis of association between PDGFA up-regulation and overall survival of patients from “Roessler set” 
belonging to different BCLC groups. 
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PDGFA, a secretable protein detectable in patient’s 
serum, may be considered as a potential HCC diag-
nostic marker at the mRNA or protein levels especial-
ly when used in combination with GPC3 to signifi-
cantly improve its low sensitivity. The association of 
PDGFA up-regulation with better overall survival of 
the patients with BCLC-0 and BCLC-A early HCC 
stages and a weaker invasion of tumor cells into blood 
vessels demonstrates that it can be accounted as a 
prognostic factor. However, this putative prognostic 
impact is limited since it is not observed in the groups 
with BCLC stages B and C. Hence, the PDGFA up-
regulation may be considered as a factor of favorable 
prognosis but the validation of this hypothesis re-
quires further studies of larger patient cohorts.
Conclusion
The present study demonstrates that PDGFA is fre-
quently overexpressed in HCC tissue. The combina-
tion of PDGFA and GPC3 performs well in distin-
guishing HCC and NT tissue when detected at the 
mRNA level. PDGFA up-regulation might have a 
prognostic potential for the patients with early HCC 
stages. We suggest that PDGFA may be a promising 
HCC diagnostic biomarker. Further studies focused 
on the detection of PDGFA in tumor tissue and se-
rum of the HCC patients are necessary to define its 
efficiency (either alone or in combination with other 
biomarkers) and the validity for improving sensitiv-
ity of the early HCC stages detection.
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Ідентифікація PDGFA як можливого біомаркера, що 
секретується, гепатоцелюлярної карциноми на підставі 
транскриптомного аналізу.
М. С. Чесноков, О. М. Кривцова, П. А. Сковороднікова, 
А. С. Макарова, И. Ф. Кустова, М. Д. Логачова, 
А. А. Пенін, A. В. Клепікова, Д. А. Шавочкіна, 
Н. Е. Кудашкін, Е. А. Мороз, Ю. В. Патютко, 
Е. А. Котельнікова, Н. Л. Лазаревич
Мета. Для діагностики гепатоцелюлярної карциноми (ГК) 
ідентифкація потенційних біомаркерів, що секретується. 
Методи. Гени, експресія яких підвищена в тканині ГК і які ко-
дують білки, що секретуються, виявляли РНК-секвенуванням. 
Експресію генів оцінювали ЗТ-ПЛР або використовували ін-
формацію з відкритих баз даних. Біомаркерні властивості оці-
нювали за допомогою ROC-кривих, аналізу кореляцій і вижи-
вання. Результати. РНК-секвенування п’яти випадків ГК вия-
вило гіперекспресію PDGFA, що кодує секретуємий білок. 
Підвищення експресії PDGFA та GPC3 виявлено в 17 з 19 зраз-
ків ГК та у більшості випадків з баз даних. Комбінація з PDGFA 
та GPC3 розрізнює тканину ГК і непухлинну тканину печінки 
краще, ніж PDGFA або GPC3 окремо. Гіперекспресія PDGFA 
асоційована з кращим прогнозом для пацієнтів з ранніми ста-
діями ГК і низькою інвазією пухлини в судини. Висновки. 
PDGFA – перспективний біомаркер ГК, що секретується, який 
може бути використаний разом з GPC3 для підвищення його 
чутливості.
Keywords: hepatocellular carcinoma; PDGFA; tumor biomarker; 
NGS
Идентификация PDGFA как возможного 
секретируемого биомаркера гепатоцеллюлярной 
карциномы на основании транскриптомного анализа.
М. С. Чесноков, О. М. Кривцова, П. А. Сковородникова, 
А. С. Макарова, И. Ф. Кустова, М. Д. Логачева, 
А. А. Пенин, A. В. Клепикова, Д. А. Шавочкина, 
Н. Е. Кудашкин, Е. А. Мороз, Ю. И. Патютко, 
Е. А. Котельникова, Н. Л. Лазаревич
Цель. Поиск потенциальных секретируемых биомаркеров для 
диагностики гепатоцеллюлярной карциномы (ГК). Методы. 
Гены, экспрессия которых повышена в ткани ГК и кодирую-
щие секретируемые белки, выявляли РНК-секвенированием. 
Экспрессию генов оценивали ОТ-ПЦР или использовали ин-
формацию из открытых баз данных. Биомаркерные свойства 
оценивали с помощью ROC-кривых, анализа корреляций и 
выживаемости. Результаты. РНК-секвенирование 5 случаев 
ГК выявило гиперэкспрессию PDGFA, кодирующего секрети-
руемый белок. Повышение экспрессии PDGFA и GPC3 выяв-
лено в 17 из 19 образцов ГК и в большинстве случаев из баз 
данных. Совместное использование двух маркерных генов 
PDGFA и GPC3 позволяет дифференцировать ткань ГК от нео-
пухолевой ткани печени лучше, чем PDGFA или GPC3 по от-
дельности. Гиперэкспрессия PDGFA ассоциирована с лучшим 
прогнозом для пациентов с ранними стадиями ГК и низкой 
инвазией опухоли в сосуды. Выводы. PDGFA – перспектив-
ный секретируемый биомаркер ГК, который может быть ис-
пользован вместе с GPC3 для повышения его чувстви-
тельности.
Keywords: hepatocellular carcinoma; PDGFA; tumor biomarker; 
NGS
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